• Non ci sono risultati.

Communicable diseases – immunization and treatment of tuberculosis

N/A
N/A
Protected

Academic year: 2021

Condividi "Communicable diseases – immunization and treatment of tuberculosis"

Copied!
2
0
0

Testo completo

(1)

Communicable diseases – immunization and treatment of tuberculosis

Immunization in the European Region

Immunization coverage has slightly increased in recent years; however, large disparities remain both between and within countries. Data from 2015 indicate that, at that time, there were still considerable differences in vaccination rates between countries. These trends have persisted over time.

Data available to WHO (but not included in the report) indicate that while immunization coverage with two doses of measles-containing vaccine increased from 88% of eligible children in 2016 to 90% in 2017, some communities reported over 95% coverage, while for others coverage was below 70%. This leaves some communities vulnerable to outbreaks of measles, which is easily preventable using the available safe and effective vaccines but which resurged in 2017 across the Region. However, the most recent data from the Regional Verification Committee for Measles and Rubella Elimination indicate that approximately 80% of European countries have interrupted endemic measles and rubella transmission for more than 12 months.

Countries where both measles and rubella remain endemic (10 for measles and 11 for rubella) are primarily middle-income countries which face significant challenges to the financial and operational sustainability of their immunization programmes. Nonetheless, in order to achieve and maintain the measles and rubella elimination target outlined in the European Vaccine Action Plan 2015–2020, it is essential that all countries, regardless of income, develop context-specific, tailored immunization interventions.

Treating cases of pulmonary tuberculosis

The average treatment success rate for pulmonary tuberculosis (TB) in the European Region has slightly increased over recent years to reach 77% in 2015. However, it still remains one of the lowest in the world. In addition, large differences between countries persist, with treatment success rates ranging from 10% to 100% (where the treatment success rate for pulmonary TB is defined as the proportion of new cases which have been registered under a national TB control programme in a given year and which have successfully completed treatment).

(2)

2 Treatment success rate for new TB cases

Source: WHO Global Health Observatory (GHO) data [website]. Geneva: World Health Organization (http://www.who.int/gho/en/, accessed 19 August 2018).

For further information, visit: http://www.euro.who.int/en/ehr2018

© World Health Organization 2018

0 10 20 30 40 50 60 70 80 90 100

2000 2003 2006 2009 2012 2015

Percentage

Maximum value reported in Region Regional average Minimum value reported in Region

Riferimenti

Documenti correlati

Notes: Based on data received 2019-11 - Surveillance data from 2019-04 to 2019-09 - * Countries with highest number of cases for the period - **WHO classifies all suspected

The monitoring report is based on measles and rubella data from The European Surveillance System (TESSy) for 1 October 2018 to 30 September 2019.. Routine disease data are submitted

The monitoring report is based on measles and rubella data from The European Surveillance System (TESSy) for 1 August 2018 to 31 July 2019.. Routine disease data are submitted on

This monitoring report is based on measles and rubella data from The European Surveillance System (TESSy) for the period 1 February 2018 to 31 January 2019.. Routine disease data

Cases classified as pending by countries are classified at WHO as clinically compatible at this time, and thus numbers might different between data shown here and provided by

Fentanyl data, in Figure 14, also shows similar trends for data from health (overdose fatalities) and criminal justice (DFS cases) sources.. Hospitalization data for fentanyl

The latest WHO data on national vaccination coverage for the first [5] and second [6] doses of measles-containing vaccine show that only four EU/EEA countries (Hungary,

GAVI supports strengthening immunization and health systems; introduction of the measles second dose through routine services; introduction of rubella vaccine through wide